Get the app
US › Healthcare

Prothena Corporation plc (PRTA)

US · Healthcare · Biotechnology

$7.97+1.01%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$1.0M
Revenue YoY
-77.1%
Net profit
$-18.6M
EPS
$-0.32
EPS estimate
$-0.39
Net margin
-1,839.9%

EPS came in at -0.32 against a street estimate of -0.39 — a beat of 17.9%.

Key statistics

Market cap
$405.0M
Forward P/E
10.6
P/B
1.47
Book value
$5.54
EPS (TTM)
$-0.82
52-week high
$11.80
52-week low
$7.73
50-day MA
$8.70
200-day MA
$9.22
Beta
-0.21

Analyst view

Analysts rate Prothena Corporation plc a buy (4 buy, 2 hold, 1 sell out of 7) with an average price target of $21.40.

Shareholding

Insiders
23.96%
Institutions
93.53%

Largest institutional holders

FundStake
FMR Inc14.02%
Rubric Capital Management LP9.74%
BlackRock Inc9.48%
State Street Corp4.66%
Acadian Asset Management LLC3.92%
Vanguard Portfolio Management, LLC3.22%
D. E. Shaw & Co LP3.14%
ADAR1 Capital Management LLC3.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prothena Corporation plc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.